Effect of intranasal administration of Orexine A [GSK 649868] on IL [interleukin]-6-system, sleep-wake-regulation and and neurocognition (NARKOREX).

Trial Profile

Effect of intranasal administration of Orexine A [GSK 649868] on IL [interleukin]-6-system, sleep-wake-regulation and and neurocognition (NARKOREX).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2009

At a glance

  • Drugs GSK 649868 (Primary)
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Acronyms NARKOREX
  • Most Recent Events

    • 08 Apr 2009 Planned end date changed from 1 Jun 2008 to 1 Aug 2009 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top